Study ACA-ARGE-04-001 "A Pilot, Open-Label Study Assessing Safety, Tolerability, Efficacy of a Simplified Lopinavir/Ritonavir Induction/Maintenance Therapy in HIV-Infected Subjects on Their First Protease Inhibitor-Based Regimen".

CompletadoFase 4ClinicalTrials.gov

ID: NCT00159224Tipo: INTERVENTIONALInicio: 1 de abr de 2005Fin estimado: 1 de dic de 2009

Traducción no disponible, mostrando original

Resumen

This study will assess the safety, tolerability and antiviral activity of a simplified PI-based treatment regimen (Kaletra,ä) compared to conventional HAART regimens in patients infected with HIV-1 who are on their first boosted-PI antiretroviral treatment regimen. The potency of the antiviral activity of Kaletra has been clearly demonstrated in a wide spectrum of patients in a number of different clinical trials.6-9 The durable viral suppression seen after 4 years of therapy10 proves that it can provide effective, long-term treatment for people with HIV-1. Data from one of these trials (M97-720),6 an ongoing Phase II study of lopinavir/ritonavir in combination with NRTIs suggests there may be a role for monoclass therapy with Kaletra in the treatment of HIV-1-infection.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Subject has confirmed his or her willingness to participate in this study after being informed of all aspects of the trial that are relevant to his or her decision to take part, by signing and dating the IRB / IEC approved informed consent form.
Subject is HIV positive and on their first antiretroviral treatment regimen, based on any two NRTIs plus lopinavir/ritonavir or a ritonavir-boosted PI combination. Subject must have had no previous exposure to other regimens.
Subject has a viral load \<50 copies/ml at the time of baseline evaluation for at least 6 months.
Subject has a CD4 cell count ³ 100 cells/mm3.
Subject is aged \>18 years.
Vital signs, physical examination and laboratory results do not exhibit evidence of acute illness.
Subject has not been treated for an active opportunistic infection within 30 days of screening.
If female, subject has a negative pregnancy test and agrees to use, for the duration of the study, a barrier method of birth control that has a history of proven reliability as judged by the investigator.
Subject does not require and agrees not to take, for the duration of the study, any medication that is contraindicated with any of the antiretroviral drugs in their treatment regimen. The subject agrees not to take any medication, including over-the-counter medicine, alcohol, or recreational drugs without the knowledge and permission of the principal investigator

Criterios de exclusión

Subject has modified his/her antiretroviral therapy during the 3 months prior to baseline or is intending to do so during the course of the study.
Subject has current uncontrolled substance abuse or psychiatric illness that could preclude compliance with the protocol.
Subject has a viral load of \> 50 copies/ml
Subject is HBsAg +
Subject has active tuberculosis or an opportunistic infection.
Subject has active malignancy (except Kaposi's Sarcoma).
Subject has liver failure as evidenced by ALT / AST \> 5 x Upper Limit of Normal (ULN).
Female subject is pregnant or lactating.
Subject has received an investigational drug within 30 days prior to the initiation of the study.

Intervenciones

drug

Lopinavir/ritonavir simplification strategy

Simplification

Ubicaciones

Helios Salud

Buenos Aires, Argentina

Fundacion Huesped

Buenos Aires, Argentina

Patrocinadores

PrincipalFundación Huésped

ColaboradorAbbott

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

Study ACA-ARGE-04-001 "A Pilot, Open-Label Study Assessin... | EligiMed